Vertex Pharmaceuticals Incorporated (VRTX)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Vertex Pharmaceuticals Incorporated (VRTX) is up 3.0% since the beginning of the year. At $467 per share, VRTX is trading 8.1% below its 52-week high of $508. Investors who bought $1,000 worth of VRTX shares 5 years ago would now be looking at an investment worth $2,489.

Vertex Pharmaceuticals Incorporated (VRTX) has returned 2.96% so far this year and 5.88% over the past 12 months. Looking at the last ten years, VRTX has achieved an annualized return of 19.01%, outperforming the S&P 500 Index benchmark, which averaged 13.88% per year.

Based on dividend-adjusted daily data since Jul 24, 1991, VRTX's average daily return is +0.12%, while the average monthly return is +2.17%. At this rate, an investment would double in approximately 2.7 years.

Historically, 55% of months were positive and 45% were negative. The best month was Feb 2000 with a return of +77.2%, while the worst month was Sep 2001 at -51.1%. The longest winning streak lasted 8 consecutive months, and the longest losing streak was 7 months.

On a daily basis, VRTX closed higher 48% of trading days. The best single day was Apr 19, 2013 with a return of +61.9%, while the worst single day was Nov 11, 2003 at -36.8%.

Vertex Pharmaceuticals Incorporated has an annualized alpha of 21.35%, beta of 1.08, and R2 of 0.11 versus S&P 500 Index. Calculated based on daily prices since July 24, 1991.

• This stock captured 128.56% of S&P 500 Index gains and 104.14% of its losses - amplifying both gains and losses, but participating more in upside than downside.
• R2 of 0.11 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

VRTX ranks 46 for risk / return — on par with similar stocks. You're getting a typical balance of risk and reward. Not a standout, but not a red flag either — a reasonable choice if other factors align with your goals.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Vertex Pharmaceuticals Incorporated. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Vertex Pharmaceuticals Incorporated was 91.77%, occurring on Nov 11, 2003. Recovery took 2677 trading sessions.

The current Vertex Pharmaceuticals Incorporated drawdown is 9.67%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Vertex Pharmaceuticals Incorporated over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Vertex Pharmaceuticals Incorporated is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.